论文部分内容阅读
目的:研究瑞格列奈联合二甲双胍对西宁地区2型糖尿病患者纤维蛋白溶酶原激活抑制因子-1(PAI-1)水平的影响。方法:选择2012年2月~2015年9月在我院进行诊治的2型糖尿病患者98例,随机分为三组,分别用瑞格列奈、二甲双胍单独治疗和两药联合治疗。在治疗前后分别检测空腹血糖、糖化血红蛋白和PAI-1水平。结果:联合用药组的治疗总有效率为94.12%,明显高于瑞格列奈组(71.87%)和二甲双胍组(75.00%)(P<0.05);瑞格列奈组和二甲双胍组治疗6周后,空腹血糖、糖化血红蛋白和PAI-1水平均明显降低(P<0.05),但两单独用药组间相比无显著性差异;联合治疗组上述指标均较单独用药明显降低(P<0.05)。联合治疗期间低血糖和胃肠不适的发生率较单独用药无明显升高。结论:瑞格列奈和二甲双胍可较单药治疗进一步降低2型糖尿病患者的PAI-1水平,这可能有助于改善患者的血液凝固程度,减少血管相关并发症,且无明显不良反应,值得临床应用推广。
Objective: To investigate the effect of repaglinide combined with metformin on the level of plasminogen activator inhibitor-1 (PAI-1) in type 2 diabetic patients in Xining. Methods: A total of 98 type 2 diabetic patients who were diagnosed and treated in our hospital from February 2012 to September 2015 were randomly divided into three groups: repaglinide, metformin alone and two drugs in combination. Fasting blood glucose, glycosylated hemoglobin and PAI-1 levels were measured before and after treatment. Results: The total effective rate of combination therapy group was 94.12%, which was significantly higher than that of repaglinide group and metformin group (75.00%, P <0.05). The repaglinide group and metformin group of 6 weeks Fasting blood glucose, glycosylated hemoglobin and PAI-1 levels were significantly lower (P <0.05), but there was no significant difference between the two treatment groups; the combination therapy group were significantly lower than the single drug treatment (P <0.05) . The incidence of hypoglycemia and gastrointestinal discomfort during the combination therapy was not significantly higher than that of the drug alone. CONCLUSIONS: Repaglinide and metformin may further reduce PAI-1 levels in patients with type 2 diabetes compared with monotherapy, which may be helpful in improving blood clotting and reducing vascular related complications in patients with no adverse reactions, which is worth Clinical application promotion.